Biotie Therapies - Company Announcement

SCIENTIFIC PAPER ON NALMEFENE IN THE TREATMENT OF ALCOHOLISM

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE
21 June, 2007

Biotie Therapies Corp. announced that the June 22nd issue of"Alcoholism: Clinical and Experimental Research", a leading journal
in addiction therapies, features a scientific article on nalmefene in
the treatment of patients with alcohol problems.

The featured study describes the results of the company's phase III
clinical study that was conducted in Finland and enrolled about 400
patients with impaired control over their alcohol drinking. According
to the results, targeted use of nalmefene during the 28 weeks of
treatment decreased heavy drinking statistically significantly. The
reduction in the number of heavy drinking days compared to placebo
was about 32%.

The company has communicated the main results of this study first in
2003.


Turku, June 21, 2007


Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Timo Veromaa, President and CEO, Biotie Therapies Corp.
tel. +358 2 274 8901, e-mail: timo.veromaa@biotie.com
www.biotie.com

Distribution:     Helsinki Stock Exchange
                  Main Media